Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Blood - 10 Sept 2009

Schnittger Susanne, Kern Wolfgang, Tschulik Claudia, Weiss Tamara, Dicker Frank, Falini Brunangelo, Haferlach Claudia, Haferlach Torsten

Abstract excerpt

Nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML), which is recognized as a provisional entity in the World Health Organization 2008 classification of myeloid neoplasms, accounts for 30% of AML. We analyzed 1227 diagnostic and follow-up samples in 252 NPM1-mutated AML patients with 17 different NPM1 mutation-specific real-time quantitative polymerase chain reaction (RQ-PCR) assays. Paired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Proto-Oncogene Proteins c-abl

Share to Stem Cell Transplantation

Share to Transplantation, Homologous

Source

Identifiers

PMID: 19587375
DOI: 10.1182/blood-2009-03-213389

Genes

NPM1
FLT3
ABL1
EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.PMID 19587375Read ↗

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.Semantic proximity Read ↗

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.Semantic proximity Read ↗

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.Semantic proximity Read ↗

Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.Semantic proximity Read ↗

Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.Semantic proximity Read ↗

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLSemantic proximity Read ↗

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.Semantic proximity Read ↗

Assessment of Minimal Residual Disease in Standard-Risk AML.Semantic proximity Read ↗

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.Semantic proximity Read ↗

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and PerspectivesSemantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

How I diagnose and treat NPM1 -mutated AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.